bg image

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

  • accueil
  • Publications
  • The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
2019 02-12

Authors: Foltyn M, Luger AL, Lorenz NI, Sauer B, Mittelbronn M, Harter PN, Steinbach JP, Ronellenfitsch MW

Abstract

Background:

Despite significant advances in the understanding of glioblastoma genetics and biology, survival is still poor. Hypoxia and nutrient depletion in the tumour microenvironment induce adaptive signalling and metabolic responses, which can influence sensitivity to therapeutic regimens. DNA damage-inducible transcript 4 (DDIT4) is a protein induced by hypoxia and in response to DNA stress. Mechanistically, DDIT4 inhibits mammalian target of rapamycin complex 1 (mTORC1) signalling by activation of the tuberous sclerosis 1/2 (TSC1/2) complex.

Methods:

Using short hairpin RNA-mediated gene suppression as well as doxycycline-regulated gene induction, we developed a glioblastoma cell model to study effects of DDIT4 under conditions of the glioblastoma microenvironment and therapy.

Results:

We found an intact DDIT4-mTORC1 signalling axis in human glioblastoma cells that was inducible by hypoxia. Temozolomide and radiotherapy also induced DDIT4 and repressed mTORC1 activity in some glioblastoma cell lines. DDIT4 gene suppression sensitised glioma cells towards hypoxia-induced cell death, while DDIT4 overexpression protected them. Additionally, in clonogenic survival analyses, DDIT4 induction conferred protection from radiotherapy and temozolomide, while DDIT4 gene suppression sensitised cells.

Conclusions:

We identified DDIT4 as a cell-intrinsic regulator for adaptive responses and therapy resistance in glioblastoma cells which may interfere with cell death induction by temozolomide, radiotherapy or hypoxia by inhibiting mTORC1 activity.

British Journal of Cancer 120pages 481–487 (2019)

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma